he issue of expensive cancer drugs is hardly new, of course, but 60 Minutes aired a segment that the other night that likely helped highlight the controversy for the mass audience that watches the popular news program. Read More
Cancer treatments that genetically modify patients’ blood cells to target the disease have shown amazing results in clinical trials. Now drug companies and biotechs must overcome big hurdles to get them into hospitals, including their potential cost. Read More
The 60 Minutes piece "The Cost of Cancer Drugs" aired on Oct. 5, 2014. Lesley Stahl is the correspondent. Richard Bonin, producer. Read More
60 Minutes, the most successful news program in American history… Read More
In response to recent reports that the cost of some generic drugs has been unexpectedly rising at a rapid clip, two members of Congress have launched an investigation and asked 14 generic drug makers to providing data about what the lawmakers called the “escalating prices they have been charging” for generic medicines. Read More
With the California-based drug manufacturer Gilead Sciences planning to roll out another hepatitis C medication, academics said Wednesday that policy changes are needed in the costly drug market so the interests of patients, health insurers and pharmaceutical companies align. Read More
A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects -- but their high cost is a growing concern. Read More
In an effort to blunt the high price of hepatitis C treatments… Read More
Winston Churchill famously described an appeaser as "one who feeds a crocodile, hoping it will eat him last." Today, in a very different context, his remark captures the plight of the American pharmaceutical industry. Read More
After recording the best launch of any drug in history, it looks like the pace is starting to slow down for Gilead Sciences' Sovaldi — the new $84,000 hepatitis C cure that's sparking a new focus on specialty drug costs. Read More
Over the last several months there has been a 'plateau and downward trend' in the use of Gilead Sciences Inc's controversial $1,000-a-pill hepatitis C treatment, Sovaldi, a CVS Health Corp analysis showed. Read More
Gilead should be commended for taking action to make their best-selling treatment for Hepatitis C, Sovaldi, available to more people around the world. In India, they’ve struck licensing agreements with generic firms to produce the product for pennies on the dollar. Unfortunately, Gilead’s largess is being funded largely on the backs of American families. Read More